KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Common Equity: 2010-2025

Historic Common Equity for TherapeuticsMD (TXMD) over the last 11 years, with Sep 2025 value amounting to $27.4 million.

  • TherapeuticsMD's Common Equity rose 1.29% to $27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.4 million, marking a year-over-year increase of 1.29%. This contributed to the annual value of $27.4 million for FY2024, which is 6.55% down from last year.
  • Per TherapeuticsMD's latest filing, its Common Equity stood at $27.4 million for Q3 2025, which was up 0.56% from $27.3 million recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Common Equity registered a high of $35.1 million during Q4 2022, and its lowest value of -$140.6 million during Q1 2022.
  • Over the past 3 years, TherapeuticsMD's median Common Equity value was $27.7 million (recorded in 2024), while the average stood at $28.4 million.
  • As far as peak fluctuations go, TherapeuticsMD's Common Equity slumped by 1,383.22% in 2022, and later soared by 219.68% in 2023.
  • TherapeuticsMD's Common Equity (Quarterly) stood at -$93.6 million in 2021, then skyrocketed by 137.54% to $35.1 million in 2022, then declined by 16.66% to $29.3 million in 2023, then dropped by 6.55% to $27.4 million in 2024, then climbed by 1.29% to $27.4 million in 2025.
  • Its last three reported values are $27.4 million in Q3 2025, $27.3 million for Q2 2025, and $26.7 million during Q1 2025.